Ensayo clínico 2026-525268-16-00 · Non Small Cell Lung Cancer

Ensayo clínico 2026-525268-16-00 (fase II) figura como «autorizado» en CTIS (EU Clinical Trials Information System).

Patología: Non Small Cell Lung Cancer · Intervenciones registradas: Lazcluze 240 mg film-coated tablets, Tafinlar 50 mg hard capsules, Vinorelbina Aurobindo 10 mg/ml concentrato per soluzione per infusione., OPDIVO 300 mg solution for injection, Tecentriq 1 875 mg solution for injection, Lorviqua 25 mg film-coated tablets, Mektovi 15 mg film-coated tablets, LIBTAYO 350 mg concentrate for solution for infusion., OSIMERTINIB, Retsevmo 80 mg hard capsules, Braftovi 50 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, LUMYKRAS 120 mg film-coated tablets, Lazcluze 80 mg film-coated tablets, Paclitaxel Fresenius Kabi 6 mg/ml koncentrat till infusionsvätska, lösning, Mektovi 45 mg film-coated tablets, Retsevmo 40 mg hard capsules, Alunbrig 90 mg film-coated tablets, Rybrevant 1600 mg solution for injection, Cisplatin Sandoz 0,5 mg/ml koncentrátum oldatos infúzióhoz, Gemcitabina Aurobindo Pharma Italia 40 mg/ml concentrato per soluzione per infusione, Rybrevant 2240 mg solution for injection, Alunbrig 30 mg film-coated tablets, TEPMETKO 225 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion., Rybrevant 350 mg concentrate for solution for infusion., KRAZATI 200 mg film-coated tablets, Alecensa 150 mg hard capsules, OPDIVO 10 mg/mL concentrate for solution for infusion., Mekinist 0.5 mg film-coated tablets, Tabrecta 200 mg film-coated tablets, Mekinist 2 mg film-coated tablets, Carboplatin Pfizer 450 mg Konzentrat zur Infusionsbereitung, Tabrecta 150 mg film-coated tablets, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed EVER Pharma 25 mg/ml koncentrat till infusionsvätska, lösning, Lorviqua 100 mg film-coated tablets, Braftovi 75 mg hard capsules, Tafinlar 75 mg hard capsules · Fechas registradas (fuente): 2026-10-19.

Fuente: https://euclinicaltrials.eu/ctis-public/view/2026-525268-16-00